Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|128-135

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 128-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

By  

Cancer, Vol. 120, Iss. 22, 2014-11 ,pp. : 3494-3501

Blackwell Publishing

Access to resources Recommend Favorite

Chronic Lymphocytic Leukemia Therapy: Beyond Chemoimmunotherapy

By  

Current Pharmaceutical Design, Vol. 18, Iss. 23, 2012-08 ,pp. : 3356-3362

Bentham Science Publishers

Access to resources Recommend Favorite

Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia

By  

Current Pharmaceutical Design, Vol. 18, Iss. 23, 2012-08 ,pp. : 3399-3405

Bentham Science Publishers

Access to resources Recommend Favorite

Pentostatin in chronic lymphocytic leukemia

By Sauter Craig   Lamanna Nicole   Weiss Mark A  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 9, 2008-09 ,pp. : 1217-1222

Informa Healthcare

Access to resources Recommend Favorite

A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia

By  

Current Medicinal Chemistry, Vol. 19, Iss. 31, 2012-11 ,pp. : 5294-5318

Bentham Science Publishers

Access to resources Recommend Favorite